Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27010531 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Irene Soleto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de M…. Hauptthemen laut MEDLINE: Hepatitis B Vaccines, Inflammatory Bowel Diseases, Hepatitis B. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Patients with inflammatory bowel disease (IBD) frequently fail to achieve protective immunity after hepatitis B vaccination, even with intensified vaccination schedules. In this observational real-world study, 18 patients with IBD who were seronegative for hepatitis B virus (HBV) received three standard doses of the Engerix-B® vaccine (at 0, 1, and 6 months). After immunisation, patients were classified into responders and non-responders according to their serological response. Blood samples were collected before the first dose and after completion of the vaccination schedule. Responders activated pathways that supported durable protection, including conventional dendritic cells type 1 mobilisation, expansion of IgG plasmablasts, and preservation of B- and T-cell memory. In contrast, non-responders displayed a more inflammatory innate profile, characterised by enrichment of CCR2+ monocytes. They also showed higher baseline Treg frequencies, which may suppress effective effector responses, together with impaired natural killer (NK) activation and progressive loss of memory potential. This study shows that hepatitis B vaccine failure in inflammatory bowel disease reflects a convergence of excessive immune regulation, inflammatory activation, and loss of memory potential, underscoring that no single pathway can explain the impaired response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades…
- Viral Immunology Laboratory, Biomedicine Department, BICS Unit, Margarita Salas Centre for Biological Research (CIB-CSIC), 28040 Madrid, Spain.
- Mucosal Immunology Lab, Instituto de Biología y Genética Molecular (IBGM, Universidad de Valladolid-CISC), 47003 Valladolid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERinfec), 28006 Madrid, Spain.
ORCID-Profile: Irene Soleto, Montse Baldan-Martin, David Bernardo, María Chaparro, Javier P Gisbert
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Soleto, I., Marin, A. C., Baldan-Martin, M., Bernardo, D., Chaparro, M., & Gisbert, J. P. (2026). Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010531
Vancouver
Soleto I, Marin AC, Baldan-Martin M, Bernardo D, Chaparro M, Gisbert JP. Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27010531
BibTeX
@article{Soleto2026,
author = {Soleto, Irene and Marin, Alicia C and Baldan-Martin, Montse and Bernardo, David and Chaparro, María and Gisbert, Javier P},
title = {Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27010531}
}
EUVIMED